Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders
NCT00437086
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Chronic Myeloproliferative Disorders
Leukemia
Interventions
DRUG:
PS-341
Sponsor
Mayo Clinic
Collaborators
[object Object]